Lacosamide NDC 72266-242

NDC codes

FDA NDC Directory

Product NDC (as listed)72266-242Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72266-0242Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72266-242-05	72266024205	5 VIAL, SINGLE-DOSE in 1 CARTON (72266-242-05) / 20 mL in 1 VIAL, SINGLE-DOSE (72266-242-01)Marketed from Nov 15, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lacosamide
Generic name (nonproprietary): lacosamide
Active ingredients: Lacosamide — 10 mg/mL
Dosage form: Injection
Route: Intravenous
Labeler: Fosun Pharma USA
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215628
Marketing start: Nov 15, 2022
Listing expires: Dec 31, 2027
DEA schedule: CV
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 72266-242_572402ba-2d76-747a-e063-6294a90ae201SPL ID 572402ba-2d76-747a-e063-6294a90ae201SPL set ID ec1c5ddb-1143-7e6a-e053-2995a90a8382RxCUI 809974UNII 563KS2PQY5

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N472266024205 followed by a unit qualifier and the quantity

Package 72266-0242-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 21, 2026.

Indications (excerpt from the label)

Lacosamide injection is indicated for: Treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older ( 1.2 ) 1.1 Partial-Onset Seizures Lacosamide injection is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Primary Generalized Tonic-Clonic Seizures Lacosamide injection is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215628

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215628
Product	Strength	Form · route	Labeler	Product NDC
Lacosamide	Lacosamide 10 mg/mL	Injection, SolutionIntravenous	Virtus Pharmaceuticals, LLC	69543-455
Lacosamide	Lacosamide 10 mg/mL	InjectionIntravenous	Gland Pharma Limited	68083-480